NEW YORK CITY, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...
The "Immunotoxins Market Size, Share & Trends Analysis Report By Product, By Application, By End-use, By Region, And Segment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results